HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Helgi van de Velde Selected Research

isatuximab

1/2022Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
1/2022Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
1/2022Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
1/2022SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
1/2022Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
12/2021Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
11/2021Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
1/2021PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
1/2021Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
1/2021Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Helgi van de Velde Research Topics

Disease

57Multiple Myeloma
01/2022 - 02/2006
18Neoplasms (Cancer)
12/2021 - 02/2006
10Peripheral Nervous System Diseases (PNS Diseases)
01/2019 - 03/2011
8Thrombocytopenia (Thrombopenia)
01/2022 - 06/2007
7Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2019 - 12/2012
5Neutropenia
01/2022 - 06/2007
5Chromosome Aberrations (Chromosome Abnormalities)
12/2021 - 04/2008
4Disease Progression
06/2019 - 08/2008
4Fatigue
01/2018 - 02/2006
4Infections
10/2015 - 08/2011
3Castleman Disease (Castleman's Disease)
10/2015 - 07/2013
3Non-Hodgkin Lymphoma (Lymphosarcoma)
05/2015 - 12/2011
2Sepsis (Septicemia)
01/2022 - 08/2014
2Pneumonia (Pneumonitis)
01/2022 - 08/2011
2Diarrhea
10/2018 - 06/2007
2Nausea
01/2018 - 08/2011
2Lymphoma (Lymphomas)
01/2018 - 08/2011
2Exanthema (Rash)
01/2017 - 04/2016
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
10/2015 - 08/2014
2Leukopenia
10/2015 - 07/2013
2Hypertriglyceridemia
10/2015 - 07/2013
2Hypercholesterolemia
10/2015 - 07/2013
2Anemia
10/2015 - 07/2013
2Multi-centric Castleman's Disease
05/2015 - 08/2014
2Immunoglobulin Light-chain Amyloidosis
10/2014 - 07/2011
2Fever (Fevers)
07/2013 - 08/2011
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
05/2013 - 08/2011
1Infarction (Infarctions)
01/2022
1Residual Neoplasm
01/2022
1Urinary Tract Infections (Urinary Tract Infection)
01/2022
1Plasmacytoma
01/2022
1Thymoma (Thymic Carcinoma)
01/2022
1Carcinogenesis
12/2021
1Cardiovascular Diseases (Cardiovascular Disease)
01/2017
1Death (Near-Death Experience)
01/2017
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2015
1Lymphopenia (Lymphocytopenia)
10/2015
1Polycythemia (Erythrocytosis)
10/2015
1Rheumatoid Arthritis
10/2015
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2015
1Amyloidosis
10/2014
1Anaphylaxis (Anaphylactic Shock)
08/2014
1Respiratory Tract Infections (Respiratory Tract Infection)
08/2014
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2014
1Heart Diseases (Heart Disease)
01/2014
1Monoclonal Gammopathy of Undetermined Significance
01/2014
1Smoldering Multiple Myeloma
01/2014
1Anorexia
07/2013
1Second Primary Neoplasms (Neoplasms, Second)
02/2013
1Ovarian Neoplasms (Ovarian Cancer)
06/2012

Drug/Important Bio-Agent (IBA)

52Bortezomib (Velcade)FDA Link
01/2019 - 02/2006
23Dexamethasone (Maxidex)FDA LinkGeneric
01/2022 - 12/2011
19Prednisone (Sone)FDA LinkGeneric
06/2019 - 10/2006
14Melphalan (Alkeran)FDA LinkGeneric
06/2019 - 10/2006
11Monoclonal AntibodiesIBA
01/2022 - 05/2013
11isatuximabIBA
01/2022 - 01/2021
10Proteasome InhibitorsIBA
01/2022 - 06/2012
10siltuximabIBA
10/2015 - 05/2013
9Lenalidomide (CC 5013)FDA Link
01/2022 - 04/2016
9ixazomibIBA
07/2020 - 04/2016
8pomalidomideIBA
01/2022 - 01/2021
8Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2019 - 01/2013
7Rituximab (Mabthera)FDA Link
01/2019 - 08/2011
7Interleukin-6 (Interleukin 6)IBA
10/2015 - 05/2013
5Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 03/2015
5Vincristine (Oncovin)FDA LinkGeneric
01/2019 - 03/2015
4Pharmaceutical PreparationsIBA
01/2018 - 05/2011
4Proteasome Endopeptidase Complex (Proteasome)IBA
01/2017 - 02/2006
3Biomarkers (Surrogate Marker)IBA
12/2021 - 05/2013
3InterleukinsIBA
10/2015 - 04/2014
2Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2021
2AlbuminsIBA
01/2022 - 04/2008
2Thalidomide (Thalomid)FDA Link
11/2015 - 01/2013
1carfilzomibIBA
01/2022
1Immunoglobulin G (IgG)IBA
01/2022
1antineoplaston A10 (A 10)IBA
01/2022
1daratumumabIBA
01/2022
1Inosine Monophosphate (IMP)IBA
06/2019
1Capsules (Microcapsules)IBA
01/2018
1Immunomodulating AgentsIBA
10/2017
1CholesterolIBA
10/2015
1HepcidinsIBA
10/2015
1Amyloid (Amyloid Fibrils)IBA
10/2014
1ErbB Receptors (EGF Receptor)IBA
04/2014
1CytokinesIBA
03/2014
1Hemoglobins (Hemoglobin)IBA
07/2013
1Adrenal Cortex Hormones (Corticosteroids)IBA
05/2013
1DNA (Deoxyribonucleic Acid)IBA
11/2012
1PlatinumIBA
06/2012

Therapy/Procedure

29Therapeutics
01/2022 - 02/2006
8Stem Cell Transplantation
07/2020 - 10/2006
4Transplantation
06/2019 - 01/2013
3Subcutaneous Injections
12/2012 - 12/2008
3Intravenous Administration
12/2012 - 12/2008
2Drug Therapy (Chemotherapy)
12/2021 - 08/2016
2Intravenous Infusions
08/2011 - 05/2011
1Retreatment
01/2019
1VAP-cyclo protocol
03/2015
1VMP regimen
06/2014
1Drug Tapering
06/2014